Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.125 USD | -1.62% | +10.83% | +7.47% |
03-08 | Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating | MT |
03-05 | Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.47% | 193M | |
+24.04% | 48.09B | |
+47.30% | 40.62B | |
-2.67% | 40.43B | |
-6.95% | 28.36B | |
+7.55% | 24.89B | |
-19.79% | 19.01B | |
+28.86% | 12.09B | |
-0.64% | 11.88B | |
-0.29% | 11.8B |
- Stock Market
- Equities
- CGEN Stock
- News Compugen Ltd.
- Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207